Jan 30, 2025, 6:00 AM
Jan 30, 2025, 6:00 AM

Colossal Biosciences raises $200 million to bring back woolly mammoths

Highlights
  • Colossal Biosciences, co-founded by Ben Lamm and George Church, focuses on de-extinction of woolly mammoths.
  • The company recently raised $200 million from investors, bringing total funds to $435 million.
  • The venture's success could lead to significant ecological impact and financial profit.
Story

In the United States, Colossal Biosciences, a company co-founded by Ben Lamm and geneticist George Church in 2021, is pursuing an ambitious agenda of de-extinction that aims to bring woolly mammoths back to the Arctic. This endeavor is premised on advancements in genetic technology, which are considered groundbreaking in the field. Recently, they secured an impressive funding round of $200 million, bolstering the total amount raised since the company's inception to $435 million, an indicator of growing investor confidence in their vision. The significant interest from investors highlights a broader trend where financial backing for biotechnologies related to genetic engineering and species revival is gaining traction. The funds are intended not only for the development of techniques that could feasibly reverse extinction but also to explore potential avenues for profit within environmental and ecological restoration markets. Colossal's founder, Ben Lamm, claims that the venture could eventually yield “tens of billions of dollars,” which further piques interest among stakeholders in various sectors. The project, while ambitious and innovative, also brings with it a set of ethical, ecological, and logistical discussions that need to be addressed. The concept of bringing back a species that has been extinct for thousands of years raises questions about the ecosystem's existing balance and the roles these animals would play in it. Proponents argue that it could contribute positively to biodiversity and fight climate change, while critics warn against unanticipated consequences. Colossal Biosciences has become a centerpiece in conversations surrounding genetic de-extinction and environmental responsibility. The potential for the company's success plays into dynamic debates about technology's role in nature management and conservation efforts. Investors and scientists alike are watching closely as this project unfolds in the coming years, which could set precedents for future endeavors in similar areas of research.

Opinions

You've reached the end